The Plasma Bioavailability of Coenzyme Q10 Absorbed from the Gut and the Oral Mucosa
Source abstract
Abstract
Coenzyme Q10 (CoQ10) has a central role in the generation of cellular bioenergy and its regulation. The hydrophobicity exhibited by the CoQ10 molecule leads to reports of poor absorption profiles, therefore, the optimization of formulations and modes of delivery is an ever-evolving therapeutic goal. The aim of this study was to investigate different CoQ10 formulations. The article summarizes the findings from an Australian comparative study involving adults administered CoQ10 through different oral delivery platforms. A total of 11 participants (six males and five females) voluntarily participated in a comparative clinical study of three different CoQ10 formulations across a six-week period, completing 198 person-hours of cumulative contribution equivalent to n = 33 participation. All of the eligible participants (n = 11) administered the three formulations blinded from who the commercial supplier of the formulation was and from what the chemical form of the CoQ10 was that was being administered. The dosing between the CoQ10 preparations were dispensed sequentially and were administered following three-week washouts. Three commercial preparations were tested, which included the following: formulations with capsules each containing ubiquinol and ubiquinone (150 mg/capsule), and a liposome ubiquinone formulation (40 mg/mL at 2 actuations of the pump). A significant inter-subject variation in the plasma level of CoQ10 at baseline that was observed to increase with an increase in age. This trend persisted in the post administration of the different formulations. Furthermore, it was observed that the intestinal absorption and bioavailability of CoQ10 varied significantly in the plasma between subjects, irrespective of whether the ubiquinol or ubiquinone forms were administered. The administration of CoQ10 as a liposome for preparation showed the poorest response in bioavailability. Although the ubiquinol capsule form of CoQ10 was observed to have increased in the plasma versus the ubiquinone capsules and the ubiquinol liposome at the two-hour interval, the inter-subject variation was such that the difference was not significant (p > 0.05). All of the CoQ10 formulations showed no further increases in their plasma levels over the remaining study period (i.e., four hours). This study further concluded that the intestinal absorption of CoQ10 is highly variable and is independent of the molecular form administered. Furthermore, it also concludes that liposomes are not an effective vehicle for the oral administration of CoQ10, and as such, did not improve the oral mucosal/sublingual absorption and bioavailability of the molecule. Of interest was the observation that with the increasing subject age, there was an observed increase in the baseline plasma CoQ10 levels in the participants prior to dosing. It was posited that the increase in the baseline plasma levels of CoQ10 with an increase in age could be due to the loss of skeletal muscle mass, a result that still needs to be verified.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Coenzyme Q10 studies and effects · Advanced battery technologies research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
The University of Sydney, Sydney Medical School, Faculty of Medicine and Health, Sydney, NSW 2006, Australia
Medlab Clinical, Sydney, NSW 2015, Australia
References (30)
Show source-provided references
1. CoQ10 a super-vitamin: Review on application and biosynthesis10.1007/s13205-018-1271-6 ↗
2. New insights into the regulation of chylomicron production10.1146/annurev-nutr-071714-034338 ↗
3. Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components10.1021/mp500193g ↗
4. Intestinal fatty acid absorption
5. Determination of coenzyme Q10 content in raw materials and dietary supplements by high-performance liquid chromatography-uv: Collaborative study10.1093/jaoac/91.4.702 ↗
6. Coenzyme q(10)--its role as a prooxidant in the formation of superoxide anion/hydrogen peroxide and the regulation of the metabolome10.1016/j.mito.2007.03.005 ↗
7. Approaches for extending human healthspan: From antioxidants to healthspan pharmacology10.1042/EBC20160091 ↗
8. Healthy aging: Regulation of the metabolome by cellular redox modulation and prooxidant signaling systems: The essential roles of superoxide anion and hydrogen peroxide10.1007/s10522-007-9096-4 ↗
9. Coenzyme q10 supplementation in aging and disease10.3389/fphys.2018.00044 ↗
10. (2015). Coenzyme q10 and statin-related myopathy. Drug Ther. Bull., 53, 54–56.10.1136/dtb.2015.5.0325 ↗
11. Statins’ effect on plasma levels of coenzyme q10 and improvement in myopathy with supplementation10.1002/2327-6924.12046 ↗
12. Coenzyme q10 as treatment for statin-associated muscle symptoms-a good idea, but10.1093/advances/nmy010 ↗
13. Coenzyme q10: Absorption, tissue uptake, metabolism and pharmacokinetics10.1080/10715760600617843 ↗
14. Relative bioavailability comparison of different coenzyme q10 formulations with a novel delivery system
15. Muneer, S., Maszood, Z., Butt, S., Anjum, S., Zainab, H., Anwar, N., and Ahmad, N. (2017). Proliposomes as pharmaceutical drug delivery system: A brief review. J. Nanomed. Nanotechnol., 8.
16. Potential of liposomes for enhancement of oral drug absorption10.2174/1567201813666160115125756 ↗
17. Formulation and evaluation of rifampicin liposomes for buccal drug delivery10.2174/1567201813666151221145617 ↗
18. A mechanistic approach to understanding the factors affecting drug absorption: A review of fundamentals10.1177/00970002042006005 ↗
19. Nanoparticles in medicine: Current challenges facing inorganic nanoparticle toxicity assessments and standardizations10.1016/j.nano.2015.05.005 ↗
20. Comparison study of plasma coenzyme q10 levels in healthy subjects supplemented with ubiquinol versus ubiquinone10.1002/cpdd.73 ↗
21. Nanotechnology safety concerns revisited10.1093/toxsci/kfm169 ↗
22. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs10.1016/j.bbrc.2015.06.177 ↗
23. Lipid-based nanovesicles for nanomedicine10.1039/C6CS00409A ↗
24. Strategies for oral delivery and mitochondrial targeting of coq1010.3109/10717544.2014.993747 ↗
25. Vitetta, L., Zhou, J., Manuel, R., Dal Forno, S., Hall, S., and Rutolo, D. (2018). Route and type of formulation administered influences the absorption and disposition of vitamin b12 levels in serum. J. Funct. Biomater., 9.10.3390/jfb9010012 ↗
26. Preparation, in-vitro and in-vivo characterisation of coq10 microparticles: Electrospraying-enhanced bioavailability10.1111/jphp.12502 ↗
27. Sarcopenia, cachexia and aging: Diagnosis, mechanisms and therapeutic options—A mini-review10.1159/000356760 ↗
28. Voice changes in the elderly10.1016/j.otc.2018.03.012 ↗
29. Plasma coenzyme q10 reference intervals, but not redox status, are affected by gender and race in self-reported healthy adults10.1016/S0009-8981(03)00137-2 ↗
30. Cellular redox activity of coenzyme q10: Effect of coq10 supplementation on human skeletal muscle10.1080/10715760290021306 ↗